Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Five (Non-COVID) Clinical Trial Misses Of 2021

Executive Summary

The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.

You may also be interested in...



Sandrock Joins Voyager As CEO To Advance New Gene Therapy Technology Into The Clinic

The former Biogen executive will succeed interim CEO Michael Higgins, who will continue as chairman.

New Player Joins Search For Effective Huntington's Therapies

Despite recent setbacks for Roche and Wave's respective antisense offerings, both those two firms and a number of other companies are trying a variety of approaches to find a treatment for Huntington's.

Novartis Hopes For Canakinumab In Lung Cancer Nosedive

After deciding to examine canakinumab's potential in lung cancer on the back of the CANTOS cardiovascular trial, Novartis designed a major late-stage program in oncology for the interleukin-1 beta inhibitor. The second of those CANOPY trials has just come crashing down.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel